Rize Oncology (XCNQ:RIZE) Change In Receivables : C$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology Change In Receivables?

Rize Oncology's change in receivables for the quarter that ended in Dec. 2024 was C$0.00 Mil. It means Rize Oncology's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Rize Oncology's change in receivables for the fiscal year that ended in Dec. 2024 was C$0.00 Mil. It means Rize Oncology's Accounts Receivable stayed the same from Dec. 2023 to Dec. 2024 .

Rize Oncology's Accounts Receivable for the quarter that ended in Dec. 2024 was C$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Rize Oncology's liquidation value for the three months ended in Dec. 2024 was C$1.54 Mil.

Rize Oncology Change In Receivables Historical Data

The historical data trend for Rize Oncology's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology Change In Receivables Chart

Rize Oncology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Rize Oncology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial												-	-	-	-	-

Rize Oncology Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Rize Oncology (XCNQ:RIZE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Rize Oncology's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Rize Oncology's accounts receivable are only considered to be worth 75% of book value:

Rize Oncology's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.656	-	0.118	+	0.75 * 0	+	0.5 * 0
=	1.54

Rize Oncology Change In Receivables Related Terms

Thank you for viewing the detailed overview of Rize Oncology's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Rize Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

RZONF:USA

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.rizeoncology.com

Rize Oncology Inc is is a biopharmaceutical company. The company is focused on the development of high-efficiency precision gene editing for human therapeutics applications. The company is also engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecules targeting soft tissue sarcoma and other cancers.

Executives

William James Garner	10% Security Holder, Director
Andre Pereira Fraga Figueiredo	Director

Rize Oncology Headlines

No Headlines